SCHEMBL1969625

SCHEMBL1969625

COC(=O)C1CN(C(=O)OC(C)(C)C)CC(C)(C)C1=O

nearest known ligand 0.41

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.41
PDE4B Q07343 2/20 0.40
RORC P51449 9/20 0.39
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
EPHX2 P34913 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5133428 0.86 RORC (0.43) NR1H2RORCDDB1CRBN
SCHEMBL4930531 0.85 PDE4B (0.39) NR1H2PDE4BRORCDDB1CRBN
SCHEMBL28760410 0.83 NR1H2 (0.39) NR1H2PDE4BRORCDDB1CRBN
SCHEMBL12364068 0.83 NR1H2 (0.40) NR1H2RORCDDB1CRBN
SCHEMBL23579409 0.79 NR1H2 (0.43) NR1H2RORCDDB1CRBN
SCHEMBL15740984 0.79 NR1H2 (0.43) NR1H2RORCDDB1CRBN
SCHEMBL19555254 0.79 RORC (0.44) NR1H2RORCDDB1CRBN
SCHEMBL12488892 0.79 RORC (0.44) NR1H2RORCDDB1CRBN
SCHEMBL29959019 0.79 NR1H2 (0.43) NR1H2RORCDDB1CRBN
SCHEMBL1835211 0.79 PDE4B (0.37) NR1H2PDE4BDDB1CRBNEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025011546-A1 HUMAN CASEINOLYTIC PROTEASE P AGONISTS AND USES THEREOF ACELON THERAPEUTICS (CN) 2025-01-16 WO disclosed
WO-2024217441-A1 GHSR 1A AGONIST, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 长春金赛药业有限责任公司 2024-10-24 WO disclosed
EP-1912979-B1 PHENYL-{3-(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2011-06-22 EP disclosed
US-20090203737-A1 Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors ADDEX PHARMA SA (CH) 2009-08-13 US disclosed
US-20080234305-A1 Novel Tetrahydropyridine Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-09-25 US disclosed
EP-1912979-A2 PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2008-04-23 EP disclosed
WO-2006123257-A2 PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-11-23 WO disclosed
EP-1673341-A1 TETRAHYDROPYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2006-06-28 EP disclosed
WO-2005040120-A1 TETRAHYDROPYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234305-A1 Novel Tetrahydropyridine Derivatives REN, AGTR1, CBR1 NR1H2 797/4885PDE4B 1977/4885RORC 2154/4885
US-20090203737-A1 Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors GRM5, GRIK5, GRM2 NR1H2 813/4885PDE4B 883/4885RORC 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.